These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone. Salido-Guadarrama AI, Morales-Montor JG, Rangel-Escareño C, Langley E, Peralta-Zaragoza O, Cruz Colin JL, Rodriguez-Dorantes M. Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843 [Abstract] [Full Text] [Related]
5. Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and 10 ng/mL. Gregorio EP, Grando JP, Saqueti EE, Almeida SH, Moreira HA, Rodrigues MA. Int Braz J Urol; 2007 Jun; 33(2):151-60. PubMed ID: 17488533 [Abstract] [Full Text] [Related]
6. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Marks LS, Song W, Wheeler TM, Slawin KM. Cancer Res; 2000 Feb 01; 60(3):756-9. PubMed ID: 10676664 [Abstract] [Full Text] [Related]
11. Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia. Fu S, Zhang X, Niu Y, Wang RT. Asian Pac J Cancer Prev; 2018 Mar 27; 19(3):699-702. PubMed ID: 29580043 [Abstract] [Full Text] [Related]
12. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Zhong W, Peng J, He H, Wu D, Han Z, Bi X, Dai Q. Clin Invest Med; 2008 Mar 27; 31(1):E8-E15. PubMed ID: 18312749 [Abstract] [Full Text] [Related]
15. [Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml]. Chen ZD, Wei SM, Cai SL. Zhonghua Wai Ke Za Zhi; 2004 May 22; 42(10):593-5. PubMed ID: 15265401 [Abstract] [Full Text] [Related]
16. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group]. Hirao Y, Ozono S, Kagebayashi Y, Yoshi M, Tani Y, Uemura H, Momose H, Okajima E. Hinyokika Kiyo; 1996 Oct 22; 42(10):795-804. PubMed ID: 8951478 [Abstract] [Full Text] [Related]
18. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. Becker C, Piironen T, Pettersson K, Björk T, Wojno KJ, Oesterling JE, Lilja H. J Urol; 2000 Jan 22; 163(1):311-6. PubMed ID: 10604382 [Abstract] [Full Text] [Related]
19. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy. De Luca S, Passera R, Fiori C, Bollito E, Cappia S, Mario Scarpa R, Sottile A, Franco Randone D, Porpiglia F. Urol Oncol; 2015 Oct 22; 33(10):424.e17-23. PubMed ID: 26162485 [Abstract] [Full Text] [Related]
20. [Comparison of PSAD and PSAD-TZ value in prostatic hyperplasia and prostatic cancer]. Fu Q, Yao DH, Jiang YQ. Zhonghua Nan Ke Xue; 2002 Dec 22; 8(6):411-3. PubMed ID: 12593013 [Abstract] [Full Text] [Related] Page: [Next] [New Search]